DSIJ Mindshare

This multibagger microcap stock receives a fresh order of Rs 6,64,00,000 - Do you own it?
Gaurav Taparia

This multibagger microcap stock receives a fresh order of Rs 6,64,00,000 - Do you own it?

The stock has given 312 per cent return in 3 years!

Vaishali Pharma Limited, a pharmaceutical company based in Mumbai, India, has announced a significant order worth Rs 664 Lakhs Approx. from the African Continent. This order not only represents Vaishali Pharma's expanding influence but also highlights its growing global reputation and geographical reach.

Key Insights

  • Vaishali Pharma has received an advance payment of Rs 332 Lakhs Approx. for the order, demonstrating the trust that clients have in the company's diverse range of healthcare products.
  • The execution of the entire order is planned for FY24, with the potential to generate substantial revenue for the company.
  • This successful transaction sets a positive tone for Vaishali Pharma's future, opening up new opportunities to contribute to healthcare needs in the African Continent and beyond.
  • The growing interest in Vaishali Pharma's offerings is a testament to the company's commitment to quality and innovation in the healthcare industry.

The stock has given 312 per cent return in 3 years!

DSIJ’s 'multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, do download the service details here.

About Vaishali Pharma Limited

It is a leading pharmaceutical company in India with over 35 years of experience. They focus on making and selling a variety of healthcare products like medicines, surgical items, and supplements for both people and animals. Vaishali Pharma is well-known in Maharashtra and has expanded globally by working with partners in places like the Democratic Republic of Congo, Kenya, and Russia. The company is committed to providing quality healthcare solutions and has become a trusted name in the industry, both locally and internationally. In FY23, the company reported Revenue of Rs 69.66 Crore, EBITDA of Rs 11.36 Crore and PAT of Rs 6.60 Crore.

Conclusion

Vaishali Pharma's recent order from Africa is a significant milestone for the company. This order not only demonstrates the company's growing global presence but also highlights its commitment to providing high-quality healthcare products to people around the world. With its strong track record and commitment to innovation, Vaishali Pharma is well-positioned for continued growth in the years to come.

Disclaimer: The article is for informational purposes only and not investment advice.

Previous Article Upper Circuit Alert: Heavy buying witnessed in this penny stock under Rs 35 following conversion of partly paid-up equity shares into fully paid-up equity shares!
Next Article Multibagger penny stock under Rs 60 with 4,000 per cent returns: Board announced bonus shares & stock split; scrip hit upper circuit!
Print
1199 Rate this article:
3.0
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR